ES2191065T3 - Linfocitos t dirigidos. - Google Patents

Linfocitos t dirigidos.

Info

Publication number
ES2191065T3
ES2191065T3 ES95937931T ES95937931T ES2191065T3 ES 2191065 T3 ES2191065 T3 ES 2191065T3 ES 95937931 T ES95937931 T ES 95937931T ES 95937931 T ES95937931 T ES 95937931T ES 2191065 T3 ES2191065 T3 ES 2191065T3
Authority
ES
Spain
Prior art keywords
lymphocytes
directed
diana
cells
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95937931T
Other languages
English (en)
Inventor
Bradley Michael John Stringer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CellFactors PLC
Original Assignee
CellFactors PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CellFactors PLC filed Critical CellFactors PLC
Application granted granted Critical
Publication of ES2191065T3 publication Critical patent/ES2191065T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LINFOCITOS T CITOTOXICOS DIRIGIDOS TIENEN UN TCR QUE COMPRENDE POLIPEPTIDOS {AL} Y {BE} HETEROLOGOS, LOS CUALES CONFIEREN AL LINFOCITO MHC DE CLASE I RESTRINGIDO ESPECIFICIDAD PARA CELULAS DIANA QUE CAUSAN ENFERMEDADES. LOS LINFOCITOS PUEDEN SER MONOVALENTES, CON UNA ESPECIE UNICA DE TCR QUE CONFIERE ESPECIFICIDAD A UNA UNICA CLASE DE CELULAS DIANA. LOS LINFOCITOS ENCUENTRAN APLICACION COMO VACUNAS Y EN INMUNOTERAPIA ADOPTIVA, P. EJ., CANCER, SIDA O TERAPIA ANTIVIRAL.
ES95937931T 1994-11-16 1995-11-16 Linfocitos t dirigidos. Expired - Lifetime ES2191065T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9423085A GB9423085D0 (en) 1994-11-16 1994-11-16 Targeted T lymphocytes

Publications (1)

Publication Number Publication Date
ES2191065T3 true ES2191065T3 (es) 2003-09-01

Family

ID=10764464

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95937931T Expired - Lifetime ES2191065T3 (es) 1994-11-16 1995-11-16 Linfocitos t dirigidos.

Country Status (16)

Country Link
EP (1) EP0792354B1 (es)
JP (1) JPH10511542A (es)
KR (1) KR970707280A (es)
AT (1) ATE231550T1 (es)
AU (1) AU687271B2 (es)
CA (1) CA2203934A1 (es)
CZ (1) CZ289455B6 (es)
DE (1) DE69529473T2 (es)
DK (1) DK0792354T3 (es)
ES (1) ES2191065T3 (es)
GB (1) GB9423085D0 (es)
HU (1) HUT77472A (es)
MX (1) MX9703535A (es)
NZ (1) NZ295418A (es)
PT (1) PT792354E (es)
WO (1) WO1996015238A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036486A2 (en) 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Scfv antibodies against disease associated molecules
IL132596A0 (en) * 1997-06-04 2001-03-19 Oxford Biomedica Ltd Vector
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
JP4238138B2 (ja) 2001-12-22 2009-03-11 ４−アンチボディ アーゲー 遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
KR101130597B1 (ko) 2005-09-13 2012-04-02 다카라 바이오 가부시키가이샤 Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
ES2719495T5 (en) 2012-05-07 2025-09-10 Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
CN106103711A (zh) 2013-11-21 2016-11-09 组库创世纪株式会社 T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用
CN110627895B (zh) * 2018-06-25 2021-03-23 北京大学 肺癌特异性tcr及其分析技术和应用
WO2023039242A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Multivalent interferon particles compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873190A (en) * 1984-06-13 1989-10-10 Massachusetts Institute Of Technology Heterodimeric T lymphocyte receptor
JP3072330B2 (ja) * 1989-07-19 2000-07-31 ジ・イミューン・レスポンス・コーポレーション 自己免疫疾患および悪性疾患の治療のためのｔ細胞リセプターペプチド
EP0722738A3 (en) * 1991-01-22 1996-10-23 Immune Response Corp Inc Vaccination and methods against diseases originating from pathogenic responses by specific populations of T cells

Also Published As

Publication number Publication date
CZ144297A3 (en) 1997-10-15
DE69529473T2 (de) 2004-01-08
CA2203934A1 (en) 1996-05-23
AU687271B2 (en) 1998-02-19
EP0792354B1 (en) 2003-01-22
WO1996015238A1 (en) 1996-05-23
GB9423085D0 (en) 1995-01-04
JPH10511542A (ja) 1998-11-10
ATE231550T1 (de) 2003-02-15
MX9703535A (es) 1997-08-30
NZ295418A (en) 2000-02-28
DE69529473D1 (de) 2003-02-27
KR970707280A (ko) 1997-12-01
AU3875495A (en) 1996-06-06
CZ289455B6 (cs) 2002-01-16
HUT77472A (hu) 1998-05-28
DK0792354T3 (da) 2003-05-19
PT792354E (pt) 2003-06-30
EP0792354A1 (en) 1997-09-03

Similar Documents

Publication Publication Date Title
ES2191065T3 (es) Linfocitos t dirigidos.
MX9203439A (es) Una citocina mamifera, il-11
CR20230303A (es) Composiciones y métodos para reducir el mhc de clase ii en una célula
ES2190432T3 (es) Activacion in vitro de celulas t citotoxicas.
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
DK421383A (da) Humant interleukin
ES2053719T3 (es) Dimetilvermectinas no naturales y procedimiento para su preparacion.
NO20001583L (no) Stimulering av hematopoetiske celler in vitro
SE8501709L (sv) Forbettringar inom eller som henfor sig till interleukinterapi
DE3684220D1 (de) Zusammensetzung mit verzoegerter abgabe.
ES2197500T3 (es) Uso de cloruro de n,n-bis(fenilcarbamoilmetil)dimetilamonio y sus usos derivados en el tratamiento del dolor cronico.
DE60017141D1 (de) Replikationskompetente anti-tumor vektoren
MX9603431A (es) Peptidos reconocidos por linfocitos citotoxicos, especificos al melanoma, y los usos para los mismos.
IL139950A0 (en) Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means
DE59407809D1 (de) Tumorizide t-lymphozyten
ES2061787T3 (es) Combinacion de inhibidores de la enzima de conversion de la angiotensina con moduladores del canal del potasio, asi como su empleo en medicamentos.
PT1007717E (pt) Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta
DE3585049D1 (de) Monoklonale antikoerper.
ES2126575T3 (es) Sacarosa-fosfato-sintasa (sps), su procedimiento de preparacion, su adnc, y utilizacion de adnc para modificar la expresion de sps en celulas vegetales.
DK4586A (da) Fremgangsmaade til formering af begoniearter
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
DE3675631D1 (de) In-vitro-kulturverfahren.
DK1107779T3 (da) Lægemidler til minipulation af T-celle immunreaktion
ES2051788T3 (es) Un producto farmaceutico.
ES2150891T1 (es) Metodo para la induccion de la muerte celular apoptodica en celulas malignas mediante la reduccion de la relacion de rb a proteinas inductoras de apoptosis.